Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 941 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Comparator 2 Clear all
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Will Hydroxychloroquine Impede or Prevent COVID-19

NCT04341441
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
Interventions
Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet, Monitoring Visit - Baseline, Monitoring Visit - Week 4, Monitoring Visit - Week 8, Weekly Assessment
Drug · Other · Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia

NCT00560937
View directory record Official record
Conditions
Schizophrenia
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 26, 2026, 5:57 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Implementation Strategies for Caregiver and Teacher Use of Behavioral Interventions: Aim 2

NCT07321327
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Symptoms
Interventions
Positive Behavior Management Toolkit for Caregivers, Positive Behavioral Management Toolkit for Teachers
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sotagliflozin Bioequivalence Study

NCT03211195
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 26, 2026, 5:57 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers Results available

Opioid-Free Pain Protocol After Shoulder Arthroplasty

NCT05488847
View directory record Official record
Conditions
Shoulder Arthropathy, Shoulder Pain
Interventions
Celecoxib, Pregabalin, Tramadol, Dexamethasone, Acetaminophen, Ropivicaine, Epinephrine, Ketorolac, Tizanidine, Magnesium, Ibuprofen, Oxycodone Hydrochloride 5 Mg
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

NCT00700817
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, sitagliptin, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Birmingham, Alabama • Escondido, California • Fresno, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis

NCT02137226
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
BI 695501, US-licensed Humira®
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
63
States / cities
Anniston, Alabama • Birmingham, Alabama • Glendale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients

NCT03139708
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Alphagan, Phenylephrine, Tropicamide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

NCT01748292
View directory record Official record
Conditions
Macular Degeneration
Interventions
0.5 mg ranibizumab
Drug
Lead sponsor
Charles C Wykoff, PhD, MD
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 26, 2026, 5:57 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

NCT03893448
View directory record Official record
Conditions
Pneumococcal Infections, Pneumococcal Vaccines
Interventions
V114, Prevnar 13™, RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, MMR II™, VARIVAX™, HIBERIX™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
1,720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
66
States / cities
Birmingham, Alabama • Dothan, Alabama • Opp, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Phase 2 Interventional

Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa

NCT01642550
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions

NCT00865761
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation

NCT02554903
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Macitentan 10mg, Placebo sugar pill
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
50
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 26, 2026, 5:57 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

NCT05304351
View directory record Official record
Conditions
Herpes Zoster, Shingles
Interventions
Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, Shingrix, Amezosvatein Adjuvant Dose Arm D, Amezosvatein Adjuvant Dose Arm F, Amezosvatein Adjuvant Dose Arm H, Amezosvatein Adjuvant Dose Arm J, Amezosvatein Adjuvant Dose Arm L
Biological
Lead sponsor
Curevo Inc
Industry
Eligibility
50 Years and older
Enrollment
1,516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2032
U.S. locations
14
States / cities
Tempe, Arizona • Coral Gables, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

NCT01975220
View directory record Official record
Conditions
Healthy
Interventions
Empagliflozin/Metformin XR FDC, 25 mg Empagliflozin/1000 mg Metformin XR, FDC, 1 tablet Empagliflozin/2 tablets Metformin XR, 1 tablet Empagliflozin/3 tablets Metformin XR
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

NCT02949388
View directory record Official record
Conditions
Chronic Stable Plaque Psoriasis
Interventions
Placebo, 400 mg (200 mg BID), 300 mg (150 mg BID)
Drug
Lead sponsor
Innovation Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Not applicable Interventional Results available

Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.

NCT01194479
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Formoterol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Comparator Dose (40mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Active Dose 1 (125 mg) MDMA HCl, Psychotherapy
Drug · Behavioral
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 26, 2026, 5:57 AM EDT
Active, not recruiting Phase 3 Interventional

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117
View directory record Official record
Conditions
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
Interventions
Oregovomab, Paclitaxel, Carboplatin, Placebo
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
81
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 70 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

NCT02684058
View directory record Official record
Conditions
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Iponeurocytoma
Interventions
Dabrafenib, trametinib, Carboplatin, Vincristine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Months to 17 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Orange, California • Washington D.C., District of Columbia • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Not applicable Interventional

Knee Arthroplasty Rehabilitation Outcomes Study

NCT02426190
View directory record Official record
Conditions
Total Knee Arthroplasty, Rehabilitation
Interventions
Anti-gravity treadmill, PENS - neuro-muscular stimulation, Anti-gravity treadmill & PENS - neuro-muscular stimulation, Recumbent or Nu-step bike
Other
Lead sponsor
MedStar National Rehabilitation Network
Other
Eligibility
40 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 26, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT04592419
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
81
States / cities
Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 26, 2026, 5:57 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Child Care Staff Weight Management Program

NCT05656807
View directory record Official record
Conditions
Obesity
Interventions
Go NAPSACC Enhanced, Go NAPSACC
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
2 Years and older
Enrollment
924 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 26, 2026, 5:57 AM EDT